Ranbaxy Laboratories Ltd has announced the following results for the quarter ended December 31, 2014:The Unaudited Standalone results for the Quarter ended December 31, 2014The Company has posted a net loss of Rs. (14204.85) million for the quarter ended December 31, 2014 as compared to net loss of Rs. (3959.60) million for the quarter ended December 31, 2013. Total Income has decreased from Rs. 13871.62 million for the quarter ended...

pdf

Ranbaxy Laboratories Limited

27 Jan 2015

Company Update

Statement

BSE India

Ranbaxy Laboratories Ltd has submitted to BSE a copy of Statement dated January 27, 2015.

pdf

Ranbaxy Laboratories Limited

22 Jan 2015

Company Update

Outcome of ESOPs Allotment Committee Meeting

BSE India

Ranbaxy Laboratories Ltd has informed BSE that the ESOPs Allotment Committee of Directors at its meeting held on January 22, 2015, allotted 6,40,597 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 425,663,497 Equity Shares of Rs. 5 each aggregating Rs. 2,128,317,485/-.

Ranbaxy Laboratories Limited

09 Jan 2015

Company Update

Shareholding Pattern For December 31, 2014

BSE India

Ranbaxy Laboratories Ltd has informed BSE about the Shareholding Pattern as on December 31, 2014.

pdf

Ranbaxy Laboratories Limited

24 Dec 2014

Board Meeting

Q3 results on Jan 28, 2015

BSE India

Ranbaxy Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on January 28, 2015, inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results for the third quarter and nine months ending December 31, 2014 (Q3) as reviewed by the Statutory Auditors of the Company....

Ranbaxy Laboratories Limited

15 Dec 2014

Company Update

Ranbaxy commences launch of India's first NCE, Synriam in African Countries

BSE India

Ranbaxy Laboratories Ltd has informed BSE regarding Press Release dated December 15, 2014 titled "Ranbaxy commenceslaunch of India's first NCE, Synriam in African Countries".

pdf

Ranbaxy Laboratories Limited

11 Dec 2014

Company Update

Ranbaxy Laboratories Ltd reply to clarification sought by the exchange

BSE India

The Exchange had sought clarification with respect to the following statement of Ranbaxy Laboratories Ltd on December 8, 2014 :"On December 5, 2014, a jury sitting in the United States District Court for the District of Massachusetts issued a verdict in the esomeprazole antitrust litigation in favor of the defendants AstraZeneca and Ranbaxy. This multidistrict litigation was commenced in 2012. As pertains to Ranbaxy, the lawsuits alleged...

Ranbaxy Laboratories Limited

08 Dec 2014

Company Update

CCI approves Ranbaxy acquisition by Sun Pharma

BSE India

Ranbaxy Laboratories Ltd has informed BSE regarding a Press Release dated December 08, 2014 titled "CCI approves Ranbaxy acquisition by Sun Pharma".

pdf

Is Ranbaxy Laboratories Limited worth buying?

5 Votes:

Buy 40.0%

Hold 60.0%